CD4 and neoplasm: TNBC and HER2+ murine models treated with peptide-pulsed DCs demonstrated increased levels of IFN-gamma secretion and antigen-specific anti-tumor CD4+ Th1 cells within the TDLN and splenocytes [48,55,56].